BEBT-260 is a highly selective ChK1 inhibitor independently developed by the company and is also the first ChK1 inhibitor to enter clinical stages in China. It is primarily intended for the treatment of advanced solid tumors with P53 mutations. Currently, there are no approved ChK1 inhibitors on the market globally, and there are limited ongoing clinical developments for ChK1 inhibitors. The company has achieved enhanced compound activity through novel structural design, reducing toxicity risks while increasing stability in human liver microsomes and S9 fractions. This significant extension of half-life contributes to improved product safety. BEBT-260 has advanced to Phase Ib clinical trials.


Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号